Danyelza
| Chemical Name | naxitamab-gqgk |
| Dosage Form | Injection (intravenous; 40 mg/10 mL, 4 mg/mL) |
| Drug Class | Monoclonal antibodies |
| System | Nervous |
| Company | Y-mAbs Therapeutics, Inc. |
| Approval Year | 2020 |
Indication
- For the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.